AI Drug Discovery Has a Verification Problem

About this video

David Finkelshteyn, CEO of Pivotal AI, joins Chris Hutchins to examine the verification gap in AI-accelerated drug discovery. They discuss model complexity, explainability, training and validation separation, pharmacokinetics, clinical trials, and why faster discovery without faster validation increases risk.

Topics covered

• Why verification has become the bottleneck in AI drug discovery
• The complexity-versus-transparency tradeoff
• Separating training and validation data to prevent leakage
• How automated labs can close the design-verification loop

This conversation is educational and does not replace clinical, legal, compliance, security, or governance review for a specific implementation.